Drug Pharmacologic Class Indication More Information
Endocrine Disorders
Tlando™ (testosterone undecanoate) Androgen For testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. FDA Approves Oral Testosterone Replacement Therapy Tlando
Gastrohepatic Disorders
Rinvoq® (upadacitinib) Janus kinase inhibitor Adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to 1 or more TNF blockers. Rinvoq Drug Monograph
Neurologic Disorders
Adlarity® (donepezil transdermal system
 Acetylcholinesterase inhibitor Treatment of mild, moderate, and severe dementia of the Alzheimer type. Donepezil Transdermal Patch Approved for Alzheimer Disease
Fintepla® (fenfluramine) Oral Solution
 Sympathomimetic Treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older. Fintepla Drug Monograph
Oncology
Lynparza® (olaparib) Poly (ADP-ribose) polymerase (PARP) inhibitor Adjuvant treatment of patients with deleterious or suspected deleterious germline BRCA-mutated human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Lynparza Drug Monograph
Opdivo® (nivolumab) Programmed death receptor-1 (PD-1) blocking antibody In combination with platinum-doublet chemotherapy, for neoadjuvant treatment of adult patients with resectable (tumors ≥4cm or node positive) non-small cell lung cancer. Opdivo Drug Monograph
Opdualag™ (nivolumab and relatlimab-rmbw) PD-1 blocking antibody and lymphocyte activation gene-3 blocking antibody For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag Drug Monograph
Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) Radioligand therapeutic agent For the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Pluvicto Approved for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

 

Topics:

Alzheimer Disease Breast Cancer Hypogonadism Melanoma Oncology Seizure Disorders Ulcerative Colitis